On Biostatistics and Clinical Trials

In my previous article, I discussed the odds ratio and risk ratio (or relative risk ratio) . In clinical trials with binary outcome, both ...

For a long time, device makers have been complaining about the FDA's device approval process . I personally heard a lot of talks that th...

According to Merriam-Webster dictionary, the word " Equipoise " means a state of equilibrium. In clinical trial, the concept of ...

We keep hearing that for patient report outcome (PRO) including patient diary data, there is no query or data clarification required and the...

From this year’s Drug Information Association (DIA) annual conference in Chicago, I learned a new concept of “Adaptive Licensing”. Accordin...

Randomization and blinding are critical components of the clinical trial from the start (design) to the end. Randomized, controlled, and ...

Bland-Altman plot is a scatter plot of variable means plotted on the horizontal axis and the differences plotted on the vertical axis wh...

Last week, I had a chance to listen to a speech by Dr Scott Gottlieb. While he touched several topics in related to the health care refor...

Working in industry setting (versus academic), we all understand that it is critical for us to be familiar with the Standard Operating P...

If you see the term “I-spy”, you would typically think something related to movie, kids game or TV series. Recently, I-spy has been linked t...

Recent discussions with my friends in China surprised me a little bit. They are way ahead in applying the advanced technology in public heal...

This Wednesday, I had a chance to attend “University of Pennsylvania Annual Conference on Statistical Issues in Clinical Trials”. The topi...

In drug development, it is necessary to understand the pharmacokinetics profiles (or time concentration profiles) of the experimental drug a...